Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sublocade injection site pharmacokinetics study in opioid dependence
ACTRN12623000691640Phase 4Suspended
- Sponsor
- Sydney Local Health District
- Start
- Dec 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of buprenorphine in opioid use disorder (OUD), sponsored by Sydney Local Health District. Primary endpoints: Pharmacokinetics of subcutaneous depot buprenorphine across four injection sites, Dose adequacy by withdrawal scales and 1 more. Started Dec 2023; status: suspended.
02
Drugs
buprenorphine
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on ACTRN12623000691640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000691640.